During the conference, Mr. Sapirstein will be available to conduct one-on-one meetings with registered investors, showcasing ...
If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...
The National Institute for Health and Care Excellence, which provides drug guidance for the NHS, said there are some side ...
Compass Therapeutics (CMPX) announced its poster presentation entitled “Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of ...
Vigil Neuroscience, Inc. ( (VIGL) ) has released its Q3 earnings. Here is a breakdown of the information Vigil Neuroscience, Inc. presented to ...
5-HT2BR agonist selectivity that maintain translational antidepressant ... partially offset by $16.1 million in proceeds from ...
Scientists develop artificial skin that can detect touch like human skin while solving electronic waste problems through a ...
Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...
The NHS in England is launching Varenicline, a once-daily pill designed to help smokers quit by reducing nicotine cravings ...
AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.
Zacks.com on MSN6dOpinion
5 Small Drug Stocks to Buy as Trump Gets Re-ElectedThe drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic ...
Wondershare UniConverter, a global leader in video conversion, is thrilled to announce the release of UniConverter V16, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback